OBJECTIVE： To prospectively study the effects of entecavir combined with Silymarin on the inflammatory markers and oxidative stress level in patients with hepatitis B virus-related decompensated liver cirrhosis （HBV-DLC）. METHODS： A total of 85 HBV-DLC patients in Hospital of Wuhan Technology University during Jan. 2015-Aug. 2016 were divided into control group （42 cases） and observation group （43 cases） according to the single and double number random. Control group was given entecavir 0.5 mg， qd. Observation group was additionally given Silymarin capsules 140 mg， tid， on the basis of control group. Both groups were treated for 48 weeks. After treatment， HBV DNA and HBeAg negative conversion rate were observed. The levels of liver function indexes （TBil， AST， ALT）， the Child-pugh score and levels of inflammatory indexes （IL-18， IL-8， TNF-α）， the levels of oxidative stress indexes （MDA， SOD， NO） were compared between 2 groups before and after treatment. The occurrence of ADR was recorded. RESULTS： Before treatment， there was no statistical significance in liver function indexes， inflammatory factors or oxidative stress indexes of 2 groups （P＞0.05）. After treatment for 48 weeks， serum HBV DNA and HBeAg negative conversion rate of observation group were higher than those of control group， but without statistical significance （P＞0.05）. Compared with before treatment， liver function indexes levels， Child-pugh score， inflammatory indexes， MDA and NO levels of 2 groups were decreased significantly after treatment for 48 weeks （P＜0.05）， while SOD level was decreased significantly （P＜0.05）； the degree of improvement of above indexes in observation group was higher than control group （P＜0.05）. There was no statistical significance in the incidence of ADR between control group and observation group （P＞0.05）， and both were improved after drug withdrawal. CONCLUSIONS： Entecavir combined with Silymarin can inhibit inflammatory reaction and relieve oxidative stress reaction to improve the liver function of HBV-DLC patients； drug combination better than entecavir alone.